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Towards optimal cut-off trough levels of
adalimumab and etanercept for a good
therapeutic response in rheumatoid arthritis.
Results of the INMUNOREMAR study
We read with great interest the paper by Chen et al1 analysing the
relationship between therapeutic response to adalimumab and
etanercept and serum drug trough levels in 70 patients with
rheumatoid arthritis (RA). The authors conﬁrmed a positive asso-
ciation between drug levels and European League Against
Rheumatism (EULAR) response. Good responders showed sig-
niﬁcantly higher drug levels than moderate or poor responders,
in line with other studies.2 3 The authors calculated (receiver
operating characteristic curves) highly sensitive and speciﬁc
cut-off trough levels of response (1.274 and 1.046 μg/mL for
therapeutic response to adalimumab and 1.242 and 0.800 μg/mL
for etanercept at 6 and 12 months, respectively). The study also
highlights the importance of establishing an optimal cut-off for
the prediction of clinical response. However, these values require
conﬁrmation in other studies and populations to be used in clin-
ical practice.
We analysed serum trough levels of adalimumab and etaner-
cept in 127 Caucasian patients with RA (81.9% women, median
age 61 years, median disease duration 13 years, duration of anti-
tumour necrosis factor therapy 60 months). The cross-sectional
study used the same bridging ELISA commercial kit and meth-
odology (Promonitor, Progenika, Biopharma, Spain) as Chen
et al.1 Fifty-four patients received adalimumab and 73 etaner-
cept (29.9% on monotherapy and 27.6% on reduced doses of
biologics). Ninety-one patients came from the prospective, mul-
ticentre INMUNOREMAR (Immunogenicity, remission and
arthritis) study4 (all with disease activity score in 28 joints
(DAS28) ≤3.2 at baseline) and 36 were patients with RA in
whom immunogenicity was assessed clinically due to active
disease (all DAS28 >3.2). Seventy-one (55.9%) patients were in
clinical remission (DAS28 ≤2.6). The accuracy and discrimin-
atory capacity of adalimumab and etanercept trough levels were
assessed by ROC curves (area under the curve (AUC)) for remis-
sion (DAS28 ≤2.6). Serum levels of adalimumab and etanercept
were signiﬁcantly higher in patients in remission than in those
who were not (median (P25–P75) adalimumab 6.9 μg/mL (2.7–
12) vs 0.5 (0.1–1), p<0.001, etanercept 2.3 μg/mL (1.5–3.1) vs
0.8 (0.4–1.8), p<0.001). For both drugs, drug levels of patients
in remission were very close to those observed by Chen et al in
patients with a good EULAR response at month 6 (adalimumab
6.5 μg/mL (3–11.5) and etanercept 2.3 μg/mL (1.4–2.3)).
In our study, analysis of accuracy with remission by DAS28 as
the reference variable showed an AUC for adalimumab of 0.81
(95% CI 0.68 to 0.94) and etanercept of 0.747 (95% CI 0.68
to 0.85). Trough levels with the greatest discriminative capacity
for remission were 1.336 μg/mL for adalimumab (sensitivity
81.9%, speciﬁcity 81%) and 1.56 μg/mL for etanercept (sensi-
tivity 71.1%, speciﬁcity 71.4%). These cut-offs were similar to
those proposed by Chen et al, especially in the case of adalimu-
mab (1.274 μg/mL for adalimumab and 1.046 μg/mL for
etanercept). The cut-off values observed in the two studies are
lower than those observed in other studies, possibly reﬂecting
detection methods or patient characteristics.2 3 5 6
In summary, the results of a study in Caucasian patients with
RA treated with adalimumab and etanercept that used a differ-
ent approach (comparing patients with and without remission
by DAS28), but the same commercial ELISA bridging test,
largely conﬁrm the results obtained by Chen et al in Asian
patients. This underlines the relationship between trough serum
levels of the two drugs and a good therapeutic response and is
further evidence in the search to ﬁnd a cut-off drug level of
response that could help optimise the management of patients
with RA receiving these drugs in clinical practice.
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